Mental Health Clinics in Pisgah Forest, NC Accepting Medicare
4 Mental Health Clinics found. Showing 1 - 4
 North Carolina Outreach Home Care, Llc Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 3431 Asheville Hwy, Pisgah Forest, NC 28768 Phone: 828-877-2112 |
Support Solutions Of The Midsouth Llc Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 3431 Asheville Hwy, Pisgah Forest, NC 28768 Phone: 828-877-2112 |
Plans For Life, Llc Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 3431 Asheville Hwy, Suite B, Pisgah Forest, NC 28768 Phone: 828-877-2897 Fax: 828-877-8299 |
Turning Point Services, Inc. Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 23 Andrew Park Way Ste 3, Pisgah Forest, NC 28768 Phone: 828-862-8016 |
News Archive
Smoke-free legislation associated with fewer hospitalizations
Smoke-free legislation was associated with substantially fewer hospitalizations and deaths from heart and respiratory diseases, according to research in the American Heart Association journal Circulation.
Bio-Path Holdings' liposomal Grb-2 IND receives FDA clearance to proceed into clinical trials
Bio-Path Holdings, Inc., a publicly traded biotechnology company with drug development operations in Houston, Texas, announced today that the U.S. Food and Drug Administration has allowed an IND (Investigational New Drug) for the Company's lead cancer drug candidate liposomal Grb-2 to proceed into clinical trials.
Hemispherx Biopharma second-quarter net loss decreases to $3.67 million
Hemispherx Biopharma, Inc. announced its financial results for the three months ended June 30, 2010. The net loss (including non-cash expenses) for the 2nd fiscal quarter was approximately $3,676,000 or $0.03 per share compared to a loss of approximately $3,870,000 or $0.04 per share for the same period in 2009.
Interim progress from Phase III TeloVac study of GV1001 vaccine announced
KAEL-GemVax, a leading oncology vaccine company, today announced, through its subsidiary GemVax A.S, encouraging interim progress from the UK-based Phase III TeloVac study of its anti-telomerase therapeutic cancer vaccine GV1001 in pancreatic cancer. The company also strongly believes GV1001 has major "blockbuster" potential as a universal therapeutic cancer vaccine and is developing a strong pipeline for other indications, including lung and liver cancer and melanoma.
Daily CHG bathing protocol for pediatric patients reduces bloodstream infections by 59%: Study
Daily bathing of pediatric patients with disposable cloths containing 2 percent chlorhexidine gluconate (CHG) reduced central line-associated bloodstream infections (CLABSIs) by 59 percent and saved approximately $300,000 in one hospital over a six-month period, according to a new study.
› Verified 2 days ago